TRPC3 and acute lymphoblastic leukemia: Supporting this model, our previous results showed that co-treatment with Dex and a TRPC3 inhibitor or cytosolic Ca2+ chelator significantly increased Δψm collapse, ROS production, cytochrome c release, and caspase-3 activity in B-ALL cells [17,18,33].